Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Development of calibrators and controls
2021-09-09

Development of calibrators and controls for DiXaIs Method validation and comparison with reference technique (LC:MS) At this stage, anti-Factor Xa bioassays can be established for reliably measuring DiXaI concentrations in plasma, with the available appropriate drug specific calibrators and co
-
Our understanding of the genetic basis
2021-09-09

Our understanding of the genetic basis of myeloid malignancies has been profoundly improved in recent years. Studies have revealed new recurrent somatic mutations in myeloid malignancies, including myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML).
-
A biochemical characterisation of this functionally crucial
2021-09-09

A biochemical characterisation of this functionally crucial LSD1-p53 interaction is the focus of this study. Using several complementary assays [29], [30], [31], [32], we find that a well-defined segment of p53-CTD is capable of binding to LSD1 active site, thereby inhibiting the enzymatic activity
-
The obtained sequence was deposited in GenBank under accessi
2021-09-09

The obtained sequence was deposited in GenBank under accession number MG703576; it showed a 99% identify with sample HE817764, reported as Demodex cornei, and with JF784000, reported as D. canis. Molecular and phylogenetic analyses and the morphological characteristics helped to rule out D. cornei.
-
br Conclusions Beta cell specific expression in
2021-09-08

Conclusions Beta cell-specific expression in human islets of DGCR2, GBF1, GPR44 and SerpinB10 has not previously been described, although the proteins have partly been characterized in other contexts not related to beta Amphotericin B sale or diabetes. DGCR2, GPR44 and SerpinB10 were negative in
-
The atherosclerosis development requires additional pro infl
2021-09-08

The atherosclerosis development requires additional pro-inflammatory response in the vascular tissue, promoting increased levels of adhesion molecules such as VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular adhesion molecule-1). Cytokines such as TNF-α and IL-1β are able to upre
-
br The methyl aspartate receptor NMDAr hypofunction hypothes
2021-09-08

The -methyl--aspartate receptor (NMDAr) hypofunction hypothesis of schizophrenia correlates disease symptomology with glutamatergic neurotransmission dysfunction., , , Therefore, inhibition of glycine transporter 1 (GlyT1) to elevate synaptic levels of glycine and potentiate NMDAr signaling is a
-
br Acknowledgement This work was
2021-09-08

Acknowledgement This work was supported in part by grants from the Ministerio de Economía y Competitividad from Spain (BFU2011-23034). Introduction The glutamate hypothesis of schizophrenia emerged from observations in the 1960s that phencyclidine and similar psychotomimetic agents produce sc
-
Natural products have been always the most
2021-09-08

Natural products have been always the most important and productive sources of lead compounds for the development of drugs [[15], [16], [17]]. A variety of potent α-glucosidase inhibitors have been identified from natural products, such as quercetin, resveratrol, isorhamnetin, calein C and curcumin
-
The effects of GHS R a
2021-09-08

The effects of GHS-R1a blockade on alcohol-related outcomes have been examined in numerous preclinical experiments, utilizing various GHS-R1a antagonists (JMV 2959, [D-Lys3]-GHRP-6, BIM 28163) and rodent species (prairie vole, mouse, rat). In spite of methodological differences, the results consiste
-
In a mouse model of hyperhomocysteinemia a risk factor
2021-09-08

In a mouse model of hyperhomocysteinemia (a risk factor for the development of vascular dysfunction) it has been shown that myoendothelial communication is enhanced due to increased expression of Cx37 and IK1 Talabostat mesylate [], allowing the propagation of endothelial signals to VSMC and thereby
-
Methods and materials Escherichia coli JM
2021-09-08

Methods and materials Escherichia coli JM109(DE3) PF-562271 mg containing a derivative plasmid of pUCmod that encodes E. coli FDPS (IspA) previously described by Schmidt-Dannert and co-workers [22] were grown in LB media containing 150μg/mL of ampilicin. E. coli was grown directly from stock cells
-
br Conclusions and perspectives br Acknowledgements This
2021-09-07

Conclusions and perspectives Acknowledgements This work was supported by the National Natural Science Foundation of China (Grant Nos. 21802173, 21405182 and 21773315), the Natural Science Foundation of Guangdong Province (Grant Nos. 2018A030310301, 201710010019 and 2014A030313232, 201804020025
-
MAP Ks act at the level of MST to phosphorylate
2021-09-07

MAP4Ks act at the level of MST1/2 to phosphorylate LATS1/2 and regulate the Hippo pathway (Box 1). Of particular interest is the involvement of MAP4K4, a key metabolic regulator [88] and common polymorphisms in the MAP4K4 locus are associated with T2D and insulin resistance [89] in adipogenesis. In
-
In first wave first generation drugs telaprevir
2021-09-07

In 2013, first-wave, first-generation drugs telaprevir and boceprevir was the first protease inhibitors (PIs) incorporated in Brazilian Clinical Guidelines for the treatment of patients infected with HCV ekb 1. Based on this 2013 Clinical Guideline, telaprevir could be used for both naïve and exper
16799 records 637/1120 page Previous Next First page 上5页 636637638639640 下5页 Last page